ArticleCPT: pharmacometrics & systems pharmacology2015
Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes.
Article in CPT: pharmacometrics & systems pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension.PloS one · 2017 · on this mapTrial
- Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients.Metabolites · 2022Article
- Application of omics in hypertension and resistant hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Review
- Plasma metabolomic profiles associated with hypertension and blood pressure in response to thiazide diuretics.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Pharmacometabolomic study of drug response to antihypertensive medications for hypertension marker identification in Han Chinese individuals in Taiwan.Computational and structural biotechnology journal · 2022Article
- Personalizing treatments for patients based on cardiovascular phenotyping.Expert review of precision medicine and drug development · 2022Article
- Pharmaco-metabolomics opportunities in drug development and clinical research.Analytical science advances · 2021Article
- Article
- How Perturbated Metabolites in Diabetes Mellitus Affect the Pathogenesis of Hypertension?Frontiers in physiology · 2021Review
- Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine.Metabolites · 2020Review
- Metabolomic profiling of metoprolol hypertension treatment reveals altered gut microbiota-derived urinary metabolites.Human genomics · 2020Article
- Cheminformatics approach to exploring and modeling trait-associated metabolite profiles.Journal of cheminformatics · 2019Article
- An Overview of Metabolic Phenotyping in Blood Pressure Research.Current hypertension reports · 2018Review
- Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension.Current hypertension reports · 2018Review
- The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety.Cardiovascular drugs and therapy · 2017Review
- Novel Applications of Metabolomics in Personalized Medicine: A Mini-Review.Molecules (Basel, Switzerland) · 2017Review
- The Future of "Omics" in Hypertension.The Canadian journal of cardiology · 2017Review
- Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.Metabolomics : Official journal of the Metabolomic Society · 2016Article
- Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans.Frontiers in pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 8 institutions in 3 countries.
Funding
Abstract
Achieving hypertension (HTN) control and mitigating the adverse health effects associated with HTN continues to be a global challenge. Some individuals respond poorly to current HTN therapies, and mechanisms for response variation remain poorly understood. We used a nontargeted metabolomics approach (gas chromatography time-of-flight/mass spectrometry gas chromatography time-of-flight/mass spectrometry) measuring 489 metabolites to characterize metabolite signatures associated with treatment response to anti-HTN drugs, atenolol (ATEN), and hydrochlorothiazide (HCTZ), in white and black participants with uncomplicated HTN enrolled in the Pharmacogenomic Evaluation of Antihypertensive Responses study. Metabolite profiles were significantly different between races, and metabolite responses associated with home diastolic blood pressure (HDBP) response were identified. Metabolite pathway analyses identified gluconeogenesis, plasmalogen synthesis, and tryptophan metabolism increases in white participants treated with HCTZ (P < 0.05). Furthermore, we developed predictive models from metabolite signatures of HDBP treatment response (P < 1 × 10(-5)). As part of a quantitative systems pharmacology approach, the metabolites identified herein may serve as biomarkers for improving treatment decisions and elucidating mechanisms driving HTN treatment responses.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.